Experts in systems biology, molecular pharmacology and bioengineering convene in Barcelona, invited by IRB Barcelona and the BBVA Foundation.
Today the “Fundación Científica de la Asociación Española Contra el Cáncer” (AECC)(Scientific Foundation of the Spanish Association Against Cancer) and the Institute for Research in Biomedicine (IRB Barcelona) have signed an agreement through which the Foundation will fund the cancer research project entitled, “Estudio de los mecanismos moleculares de la metástasis del cáncer de mama a pulmón: función y potencial terapéutico de genes supresores de metástasis” (Study of the molecular mechanisms of metastasis of breast cancer to the lung: therapeutic function and potential of metastasis suppressor genes). The signing of this agreement was done in IRB Barcelona...
The study, headed by Joan Massagué in New York, has involved researchers at IRB Barcelona and Hospital Clínic-IDIBAPS.
Researchers at IRB Barcelona have demonstrated that the decrease in Dab1 protein expression caused by the infective action of prions also reduces the production of β-amyloid, a risk factor of Alzheimer’s disease.
Epilepsy, cancer, diabetes and depression are just some examples of the severe diseases associated with mutations in these proteins.
The biotech company Omnia Molecular shared by IRB Barcelona, opens its new facilities in the Barcelona Science Park.
Otorgado por la revista Actualidad Económica y el diario Expansión
Researchers study the evolution of life by examining the translation of the genetic codes of several organisms, in order to discover differences between bacteria and humans that allow the design of new antibiotics
The finding of researchers at the Barcelona Supercomputing Center (BSC) and the Institute for Research in Biomedicine (IRB Barcelona) has been possible thanks to the calculation capacity of the MareNostrum supercomputer.
The European Research Council has awarded Eduard Batlle a Starting Grant for outstanding young researchers